This Strange Little Stock Could Be Insanely Profitable For Early Investors

I recently listened to a compelling interview with Kevin O’Leary from ABC’s Shark Tank where he laid out his bullish case for investing in psychedelic medicine stocks… And I was quite intrigued.

O’Leary drew parallels between the early days of the medical marijuana industry to psychedelic medicines today.

Just like the CBD component of cannabis is thought to have medical benefits, the psilocybin component of psychedelics could do the same.

Now that Colorado, Oregon, and Washington DC have decriminalized certain psychedelics like magic mushrooms and LSD, legal medical trials are commencing with FDA approval and publicly traded companies stand to benefit if successful.

By far and away, the most interesting stocks in the space is Mind Medicine (MindMed) Inc. (NASDAQ: MNMD).

O’Leary is a major shareholder after taking part in the company’s most recent $6.2 funding round.

When asked why he took a stake in the company, he said, “This could save lives, cure depression, help alcoholism, get people off opioids – why wouldn’t I want to be invested?”

Other research I’ve read indicates psychedelics could also help people suffering from Alzheimer’s, anxiety, depression, anorexia, schizophrenia, opioid addiction, and more…

MindMed also only intends to pursue the medical psychedelic space. It has no intention of becoming a company that sells recreational drugs.

O’Leary went on to say that MindMed has more trials going on around the world than any other company in the space. So that’s what he thinks gives the company the best chances of success versus its competitors.

It currently has multiple trials in Phase I and Phase II studies – no psychedelic company has one in Phase III yet.

That tells me two things:

1) We’re still so early that the room for growth is absolutely massive considering the size of the opioid industry in the U.S. is $500 billion alone.

And 2) There’s still tremendous risk us early investors would have to take in order to help fund these early studies.

But with that risk comes the possibility for insanely high returns.

Regardless, whatever you do, make sure you conduct more research before investing.

The more I read though, the more fascinated I'm becoming with MindMed the entire psychedelic space.

NEXT: The #1 Biotech Stock of 2021 (New Report)

EV Play No One's Talking About

This company is a sneaky EV play that no one’s talking about. They’re producing the “oil” of electric vehicles and could hand big returns to the first movers.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy


By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. We will never share your email address, and you can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$30 Stock Freaking Out Billionaires

This stock is an industry leader in a robotics technology that is freaking out billionaires (trading for just $30).

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy


By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. We will never share your email address, and you can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

The Best TaaS Stock Right Now

This company is set to corner the market in a self-driving technology that  could fundamentally change our entire society – much like the internet did.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy


By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. We will never share your email address, and you can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Up to 20,000 IPOs All in One Day

A radical $2.1 quadrillion shift is coming to the financial markets.

Some are calling it G.T.E. and Mark Cuban, Elon Musk, Richard Branson, and even banks like J.P. Morgan are invested in the tech behind it.

Just $25 could get you in alongside these billionaires. 

Enter your email address to receive the video that reveals it all.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy


By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. We will never share your email address, and you can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$2 Biotech Stock

Steve Cohen, the billionaire stock picker known for running one of the most successful hedge funds ever, has poured millions into the first stock, and it’s trading for only $2.

Enter your email address to receive this company’s name and ticker symbol for free.


Free Bonus E-Book: The Second Wave Why popular tech stocks could be in store for a 92% meltdown and the #1 investment billionaires are turning to now... from Morning Bullets. Privacy Policy


By submitting your email address, you give Stock Market Junkie permission to 1. deliver the report or research you're requesting to your email inbox, 2. send free ongoing updates via our independent financial email newsletter, and 3. share carefully selected marketing offers for product and services we think will interest you. Your privacy and security are paramount to us. We will never share your email address, and you can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works